

ICON Reports Strong Results with 24% increase in operating income in First Quarter FY 2005 (NASDAQ:ICLR)

Highlights – First Quarter Fiscal 2005

- * First Quarter net revenues increased 14% over the first quarter of fiscal 2004 to \$78.3 million.
- * Income from operations increased by 24% over the first quarter of fiscal 2004 to \$9.5 million.
- * Diluted earnings per share increased 18% for the first quarter to 52 cents compared to 44 cents for the same quarter last year.
- * \$93 million of gross (\$46 million net) new business awarded to ICON during the quarter.

Dublin, Ireland, September 28, 2004 – ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which has over 2,550 employees providing services to the pharmaceutical, biotech and medical device industries from 35 locations in 21 countries worldwide, today reported the financial results for its first quarter ended August 31, 2004.

Net revenues for the quarter were \$78.3 million, representing a 14% increase over net revenues of \$68.9 million for the same quarter last year. Excluding the impact of acquisitions, revenue growth was 8% over the same quarter last year.

Income from operations was \$9.5 million, which represents an increase of 24% from the \$7.6 million reported for the first quarter last year. Operating margin for the quarter was 12.1%, compared with 11.1% for the equivalent period last year. Net income for the quarter was \$7.3 million or 52 cents per share, on a diluted basis, compared with \$5.6 million or 44 cents per share for the first quarter last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 59 days at August 31, 2004, a decrease from the 60 days reported at May 31, 2004.

For the quarter ending August 31, 2004, capital expenditure was \$4.5 million and \$9.9 million was paid in relation to the acquisition of 70% of the common stock of Beacon Biosciences Inc, on July 1, 2004. As a result, the company's net cash, short-term debt and short-term investments were \$65.6 million at August 31, 2004, compared to \$78.8 million at May 31, 2004.

"We are pleased with the performance in our first quarter of fiscal 2005", commented Chairman Dr. John Climax. "Our operating margins were strong, earnings per share increased by 18% and we made further progress on our strategic development with the acquisition of a 70% interest in Beacon Biosciences, Inc".

Commenting on the outlook, Dr Climax said "As previously indicated, due to the high level of recent delays and cancellations we expect a small sequential decline in revenues for our second quarter of Fiscal 2005. We remain confident in the outlook for the business and anticipate a re-establishment of revenue growth in the second half of the year."

The company will hold its first quarter conference call today, September 28, 2004 at 08:00 EST [13:00 Ireland & UK / 14:00 CET]. This call and linked slide presentation can be accessed live from our website at <http://www.iconclinical.com>. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "shareholders services". This calendar will be updated regularly.

The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

The financial information presented herein has been prepared in accordance with U.S. GAAP.

Source: ICON plc

Contact : Investor Relations 1-888-381-7923 or
Sean Leech CFO + 353 –1-291-2000
Both at ICON.

<http://www.iconclinical.com>

ICON plc

Consolidated Income Statements (Unaudited)

Three months ended August 31, 2004 and 2003
(Dollars, in thousands, except share and per share data)

	Three Months Ended	
	Aug 31, 2004	Aug 31, 2003
Gross Revenue	\$117,195	106,177
Subcontractor costs	38,856	37,242
Net Revenue	<u>78,339</u>	<u>68,935</u>
Costs and expenses		
Direct costs	42,453	37,699
Selling, general and administrative	23,339	21,025
Depreciation	3,062	2,589
Total costs and expenses	<u>68,854</u>	<u>61,313</u>
Income from operations	9,485	7,622
Interest income (net)	164	47
Income before provision of income taxes	<u>9,649</u>	<u>7,669</u>
Provision for income taxes	2,322	2,065
Minority Interest	<u>22</u>	<u>-</u>
Net income	<u><u>7,305</u></u>	<u><u>5,604</u></u>
Net income per ordinary share		
Basic	<u>\$0.53</u>	<u>\$0.46</u>
Diluted	<u>\$0.52</u>	<u>\$0.44</u>
Weighted average number of ordinary shares		
Basic	13,837,986	12,153,772
Diluted	14,105,288	12,606,971

ICON plc

Summary Balance Sheet Data

August 31, 2004 and May 31, 2004
(Dollars, in thousands)

	August 31, 2004 (unaudited)	May 31, 2004 (audited)
Cash and short-term investments	72,573	78,763
Short-term debt	(7,000)	-
Net cash	65,573	78,763
Accounts receivable	70,125	74,079
Unbilled revenue	66,984	59,861
Payments on account	(61,376)	(61,960)
Total	75,733	71,980
Working Capital	110,411	113,813
Total assets	341,016	335,323
Shareholder's equity	222,454	216,760

Source: ICON plc

Contact: Investor Relations 1-888-381-7923 or
Sean Leech CFO + 353 1 291 2000
both at ICON.

<http://www.iconclinical.com>